At Firstmed, we're inspired by a single goal: your health. That's why we're dedicated to developing new, safe medicines to prevent and treat the world's most serious diseases. And why we are making them available to the people who need them most. We believe that from progress comes hope and the promise of a healthier world.

Firstmed Pipeline – Our Medicines in Development

Our pipeline of new medicines in development is the largest in the pharmaceutical industry, focusing on a broad range of unmet medical needs spanning 3 Therapeutic Areas. Firstmed invests in the research and development of new products across several therapeutic areas. Relying on the strength of our pipeline and scientific talent, Firstmed has generated a steady stream of breakthroughs over the years. Our researchers continue to work around the clock and around the globe to ensure the best medicines for our patients in the years to come.

Cardiovascular, Metabolic and Endocrine Diseases
Chronic cardiovascular disease and diabetes cause one of every three deaths in the world today. Unless breakthroughs are made, the growing prevalence of diabetes and obesity will greatly add to the human and economic cost of disease over the next 20 years. Advances in understanding risk factors and in the development of new therapies have demonstrated that cardiovascular disease is largely preventable. Firstmed´s current and future portfolio of medicines in this Therapeutic Area focuses on the control of the risk factors inherent in smoking, diet, physical inactivity, and Type 2 diabetes.

Genitourinary/Sexual Health
Genitourinary (GU) conditions account for a major source of distress for millions of people throughout the world. While many GU conditions are manageable, patients often do not seek treatment due to either the dismissal of these conditions as “merely quality of life” issues, or the embarrassment and misunderstanding associated with their symptoms and conditions. In response, Firstmed is working to help these patients.

Pain
In recent years there have been very few breakthrough medicines for the treatment of chronic pain, with many of the current standard medicines dating back decades (if not centuries). The result of this is that there are still millions of patients across the world for whom there is no adequate medicine to treat their pain. The impact of pain is profound. Frequent sufferers are stopped from working, sleeping, and socializing, with a common result of depression.

Firstmed’s pain team hopes that new insights into the causes of pain, and new ways to actually ‘measure’ it, can help usher in a series of new medicines that will provide greater relief from the symptoms of pain, allowing patients to return to normal lives at work and at home.